Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...
The world’s first early-detection blood test for pancreatic cancer is set to be launched in Australia, and is predicted to ...
4don MSN
Pancreatic cancer is among the deadliest cancers: New drug is giving patients and doctors hope
Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...
HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...
Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...
Windsor resident beating the odds following devastating diagnosis and treatment for usually deadly form of pancreatic cancer.
Misconceptions about HCC often lead to stigma, but early detection can significantly improve treatment outcomes and survival ...
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma Hong Kong, Shanghai & Florham Park, NJ — ...
Hong Kong, Shanghai Tuesday, January 6, 2026, 13:00 Hrs [IST] ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase ...
RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback